Discontinued — last reported Q4 '24
Products & Services · Research and development:
QALSODY — Research and development:
Biogen QALSODY — Research and development: remained flat by 0.0% to $5.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $4.00M to $5.00M.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2024
Rolls up toR&D
How to read this metric
An increase often signals active investment in clinical trials or lifecycle management, while a decrease may indicate the completion of development phases or a shift in strategic focus.
Detailed definition
This metric captures the total direct costs associated with the research, clinical development, and regulatory approval...
Peer comparison
Comparable to asset-specific R&D expense reporting common in pharmaceutical segment disclosures.
Metric ID:
biib_segment_qalsody_research_and_developmentHistorical Data
2 years
| FY'23 | FY'24 | |
|---|---|---|
| Value | $16.00M | $20.00M |
| YoY Change | — | +25.0% |
Range$16.00M – $20.00M
Avg YoY Growth+25.0%
Median YoY Growth+25.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's qalsody — research and development:?
- Biogen (BIIB) reported qalsody — research and development: of $5.00M in Q4 2024.
- How has Biogen's qalsody — research and development: changed year-over-year?
- Biogen's qalsody — research and development: increased by 25.0% year-over-year, from $4.00M to $5.00M.
- What does qalsody — research and development: mean?
- The total costs incurred to research and develop a specific pharmaceutical product.